Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Revenues
Royalty and licensing revenue	$ 0	$ 1,121
Treatment investment revenue	22	0
Total revenue	22	1,121
Operating expenses
General and administrative	4,020	1,216
Research and development	1,608	442
Selling expenses	0	42
Total operating expenses	5,628	1,700
Loss from operations	(5,606)	(579)
Other income (expense)
Interest income (expense), net	7	(2)
Loss on settlement of accrued liability	(33)	0
Loss on foreign exchange	(1)	(20)
Total other expense	(27)	(22)
Net loss	$ (5,633)	$ (601)
Loss per share of common stock:
Basic and diluted (in dollars per share)	$ (2.77)	$ (0.30)
Weighted average common stock outstanding
Basic and diluted (in shares)	2,032,433	1,992,433